---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-013169"
form_type: "8-K"
ticker: "ALT"
cik: "0001326190"
company_name: "Altimmune, Inc."
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T00:41:30.176549+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Altimmune Q2 net loss $20.1M ($0.42/share); cash $184.8M; pemvidutide Phase 1b data mid-Sept

## Summary
- Net loss of $20.1M ($0.42 per share) for Q2 2022 vs $24.8M ($0.60) in Q2 2021, which included $8.1M impairment.
- Cash, equivalents, and short-term investments $184.8M at June 30, 2022.
- R&D expenses $16.0M in Q2 2022, up from $13.3M, primarily on pemvidutide development.
- Pemvidutide Phase 1b obesity/NAFLD topline data expected mid-September 2022; Phase 2 MOMENTUM interim analysis (160 subjects) expected Q1 2023.
- HepTcell Phase 2 chronic hepatitis B trial enrollment ongoing; data expected H2 2023.

## SEC filing metadata
- accession: 0001558370-22-013169
- form_type: 8-K
- ticker: ALT
- cik: 0001326190
- company_name: Altimmune, Inc.
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326190/000155837022013169/0001558370-22-013169-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326190/000155837022013169/alt-20220811x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-013169
- JSON: https://secwatch.observer/filing/0001558370-22-013169.json
- Plain text: https://secwatch.observer/filing/0001558370-22-013169.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.